Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at  years is % or greater
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
STEP I: Prior systemic glucocorticoid use for the treatment of non-malignant disorders is permitted; prior or concurrent topical or localized glucocorticoid therapy to treat non-malignant comorbid disorders is permitted
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Recurrent or multifocal malignant gliomas
Patients must have had cytology within  days prior to registration; cytology for patients with CIS component is not expected to be negative for malignant cells; if the cytology for patients with only Ta/T disease is positive for malignant cells, patient must have had a biopsy of the prostatic urethra within the previous six months
Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled
Any evidence of tumor metastasis or co-existing malignant disease
Malignant disease, other than that being treated in this study.
Other malignant diseases than the ones being treated in this study
Malignant disease, other than that being treated in this study.
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Malignant CNS disease that has not been definitively treated
Malignant disease, other than that being treated in this study
At high medical risk because of non-malignant systemic disease including uncontrolled infection
Patients with malignant disease other than that being treated in the study.
Participants may have underlying malignant or non-malignant hematologic disease, except for primary immunodeficiency, as the indication for their allogeneic HSCT; patients with immune dysregulation syndromes such as familial or secondary hemophagocytic lymphohistiocytosis (HLH) are eligible
Known distant metastatic disease (e.g. pulmonary or hepatic metastases)\r\n* Subjects with malignant lymphadenopathy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadnectomy with the goal of complete resection of all malignant disease are allowed
Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past  years
Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugs
No clinical or radiographic evidence of malignant regional adenopathy
Concurrent, malignant disease for which patient is on active therapy
A history of pneumonitis or extensive bilateral lung disease of non-malignant etiology.
All malignant disease must be able to be encompassed within a single irradiation field
Less than % malignant cells in the peripheral blood leukocytes
More than one concurrent, malignant disease
Visible additional disease that suggests a greater than T malignant melanoma
Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last  months
Active malignant relapse
Less than % malignant cells in the peripheral blood leukocytes
Malignant disease other than that being treated in this study.
Cohort : Any solid malignant tumor.
INCLUSION CRITERIA FOR ENROLLMENT: Expectation of ability to safely undergo salvage treatment appropriate for the patients malignant disease type
patients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.
INCLUSION CRITERIA FOR CCT: patients must have the diagnosis of malignant chromaffin cell tumor (CCT) i.e. malignant pheochromocytoma or malignant paraganglioma
Malignant disease, other than that being treated in this study
Presence or history of a malignant disease other than the study related cancer
Subjects diagnosed with other malignant primary tumor
Malignant disease, other than that being treated in this study.
In addition, patients with NF and with malignant peripheral nerve sheath tumor (MPNST)
Diagnosis of \tumor of low-malignant potential\.
Recurrent malignant gliomas
Other non-malignant systemic disease that would preclude treatment with any of the treatment regimens or would prevent required follow-up
A prospective patient for allogeneic hematopoietic stem cell transplant (HSCT) for hematologic conditions, both malignant and non-malignant; donor can be unrelated marrow or peripheral blood cells; a patient with history of central nervous system (CNS) involvement is eligible if CNS disease is in remission at time of study consideration
Existing non-malignant disease that would preclude the administration of pasireotide
Patients with any non-malignant intercurrent illness (e.g. cardiovascular, pulmonary, central nervous system disease) which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the patient on protocol
Epithelioid malignant peripheral nerve sheath tumor
Epithelioid malignant peripheral nerve sheath tumor
Acute and chronic, active infectious disorders and non malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy
Diagnosis of malignant disease within the previous  months
Prior or concurrent malignant disease unless cured for more than five years.
Patients must have no non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with protocol therapy
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within  months before the first dose of any study drug, except for hydroxyurea.
Any other malignant disease
Concurrent, malignant disease for which patient is on active therapy
Currently have mesothelioma of the sarcomatous type, mixed histologic disease, or have malignant peritoneal mesothelioma
Malignant disease, other than that being treated in this study
Active malignant relapse
Participants with active malignant relapse or recrudescence of their prior hematologic disorder
Extension of malignant disease into the anal canal
Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last  months
Patients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.
Known history of malignant hypertension
All malignant disease must be able to be encompassed within a single irradiation field
Any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy
Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled
Prior investigational agents for malignant or non-malignant disease within  weeks prior to Day 
History of malignant peripheral nerve sheath tumor
Acute and chronic active infectious disorders and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy
Known history of malignant hypertension.
Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled or the control of which may be jeopardized by this therapy
 Known history of malignant hypertension.
Prior gastrectomy (partial or total) for the underlying malignant disease under investigation
Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up
Does not have any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy
High medical risks because of non-malignant systemic disease or with active uncontrolled infection;
No other drug treatment for malignant melanoma administered after completing study treatment with trametinib
Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT
Alkaline phosphatase > . x ULN (unless due to lymphoma or a non-malignant, non-hepatic cause such as Paget's disease)
Non-malignant disease that would render the patient unsuitable for treatment according to the protocol.
Presence of other malignant diseases, except non-melanoma skin care
Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugs
Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past  years.
Women with non-palpable malignant lesions, requiring image guided localization.
With diagnosis of malignant or benign disease
Is known or suspected to have a (family) history of malignant hyperthermia
Patients undergoing myeloablative allogenic hematopoietic stem cell transplant for any indication (both malignant and non-malignant) are eligible
Non-malignant pain
TRANSPLANT PATIENTS: all patients undergoing planned allogeneic transplant (both malignant and non-malignant diagnoses)
Evidence of active malignant disease
History of neuroleptic malignant syndrome
Active malignant disease relapse
Active malignant relapse
Known primary benign or malignant hematologic disorder which can cause anemia.
Participants must not have evidence of active/recurrent malignant disease for a minimum of  months.
Participants must not have evidence of active/recurrent malignant disease for  months
Must be underdoing allogeneic or autologous HCT for a malignant or non-malignant disorder
Other concurrent clinically active malignant disease, requiring treatment
Patients with either pre-malignant or a history of oral cancer based on patient history and clinical presentations
Patient is considered a poor risk for surgery due to non-malignant systemic disease (cardiovascular, renal, etc.) that would preclude the treatment options
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
